Table 3.

Summary of efficacy data from phase II/III trials of emerging anti-angiogenic agents in recurrent ovarian cancer

Study (n)	Regimen	ORR (CR + PR), %	Median PFS, months	Median OS, months
Matulonis et al. [42]	Cediranib 45 mg/day	17	5.2	Not reached
(n = 46)
Ledermann et al. [43]	Cediranib 20 mg/day → cedarinib maintenance vs. placebo	–	Restricted mean survival time, months	Restricted mean survival time, months
(n = 456)			11.4 vs. 9.4	20.3 vs. 17.6
Du Bois et al. [44]	Pazopanib 800 mg/day vs. placebo	–	17.9 vs. 12.3	Not reached
(n = 940)
Campos et al. [45]	Sunitinib 37.5 mg/day	8.3	9.9b	–
(n = 35)
Biagi et al. [46]	Sunitinib 50 mg/day (int.)	13.3	4.1	–
(n = 30)
Baumann et al. [47]	Sunitinib 50 mg/day (int.) vs. 37.5 mg/day (cont.)	16.7 vs. 5.4	4.8 vs. 2.9	13.6 vs. 13.7
(n = 73)
Matei et al. [48]	Sorafenib 400 mg b.i.d.	3.4	6-month PFS rate: 24%	–
(n = 71)
Herzog et al. [49]	Sorafenib 400 mg b.i.d. vs. placebo	–	386 vs. 478a	–
(n = 249)
Ledermann et al. [50]	Nintedanib 250 mg b.i.d. vs. placebo	–	36-week PFS rate:	–
(n = 83)			16.3% vs. 5.0%
Du Bois et al. [51]	Nintedanib 200 mg b.i.d. + CP vs. nintedanib + placebo	–	17.3 vs. 16.6	–
(n = 1,366)
Coleman et al. [52]	Aflibercept 6 mg/kg + D	54	6.2	24.3
(n = 46)
Gotlieb et al. [53]	Aflibercept 4 mg/kg vs. placebo	–	6.3 vs. 7.3b	12.9 vs. 16.0b
(n = 55)
Colombo et al. [54]	Aflibercept 4 mg/kg	–	8.5b	–
(n = 16)
Karlan et al. [55]	Trebananib 10 mg/kg + P vs. trebananib 3 mg/kg + P vs. placebo + P	37 vs. 19 vs. 27	7.2 vs. 5.7 vs. 4.6	22.5 vs. 20.4 vs. 20.9
(n = 161)
Monk et al. [56]	Trebananib 15 mg/kg + P vs. placebo + P	38 vs. 30	7.2 vs. 5.4	19.0c vs. 17.3c
(n = 919)

b.i.d. = twice daily. cont = continuous. CR = complete response. D = docetaxel. int = intermittent. ORR = objective response rate. OS = overall survival. PFS = progression-free survival. P = paclitaxel. PR = partial response.

^aTime in days.

^bTime in weeks.

^CInterim data.